Sanofi, Regeneron get Dupixent EC approval for eosinophilic esophagitis
French pharmaceutical company Sanofi and Regeneron, an American biotechnology company, have received the approval of the European Commission (EC) to market their Dupixent (dupilumab) injection ... Read More
Dupixent delivers positive results in eosinophilic esophagitis trial
Regeneron Pharmaceuticals and Sanofi said that their co-developed eczema drug Dupixent (dupilumab) has met the co-primary endpoints of Part A of a phase 3 trial ... Read More
Dupixent receives FDA approval for treatment of moderate-to-severe asthma
Sanofi and Regeneron Pharmaceuticals' Dupixent (dupilumab) has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) approving it as an add-on maintenance ... Read More